Anil Poulose, MD
Interventional Cardiology · Minneapolis, MNNPI 1528078458
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,934 of the $3,934 with a category attached, or 74.6%. 5 manufacturers reported payments, led by Edwards Lifesciences at 51.7% of the total. That places this record below the midpoint for interventional cardiology clinicians in MN, where the typical reported total is $5,396.
Across 48 payments — averaging $81.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$2K
- Abiomed$870
- Medtronic$558
- Abbott$409
- Boston Scientific$64
Across 45 payments — averaging $2465.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$56K
- Abbott$55K
What the payments were for
- Travel & lodging$1,00025%
- Food & beverage$2,93475%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 24 | $2,033 |
| Abiomed | 11 | $870 |
| Medtronic | 5 | $558 |
| Abbott | 6 | $409 |
| Boston Scientific | 2 | $64 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,934 in reported general payments places this provider in the 40th percentile of 84 interventional cardiology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 72 | $98,385 |
| EntrestoSacubitril/Valsartan | 30 | $42,687 |
| XareltoRivaroxaban | 12 | $17,838 |
| Repatha SureclickEvolocumab | 13 | $16,503 |
| Praluent PenAlirocumab | 12 | $8,185 |
| FarxigaDapagliflozin Propanediol | 12 | $7,773 |
| Metoprolol Succinate | 184 | $2,576 |
| Rosuvastatin Calcium | 89 | $1,274 |
| Atorvastatin Calcium | 101 | $1,212 |
| Losartan Potassium | 82 | $1,072 |
| Ezetimibe | 27 | $782 |
| Amlodipine Besylate | 76 | $760 |
| Furosemide | 52 | $523 |
| ClopidogrelClopidogrel Bisulfate | 51 | $514 |
| Metoprolol Tartrate | 52 | $485 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Minneapolis
- Emmanouil BrilakisMinneapolis$548K
- Wesley PedersenMinneapolis$493K
- Michael ManolesMinneapolis$201K
- Jay TraverseMinneapolis$198K
- Robert WilsonMinneapolis$176K
- Yale WangMinneapolis$168K
- Steven RohMinneapolis$67K
- Stefan BertogMinneapolis$64K
- Konstantinos VoudrisMinneapolis$46K
- Michael MooneyMinneapolis$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.